First Trust NYSE Arca Biotechnology Index Fund (NYSEArca: FBT)
2012: 40.7%
2013: Up 42%
Comment: FBT is another biotech ETF that has a chance to do double duty on the “best of” sector lists for 2012 and 2013. The $919 million FBT differs from BBH in that it offers lower exposure to the Amgen/Celegen/Biogen (Nasdaq: BIIB), Gilead (NasdaqGM : GILD) crowd and that means more exposure to mid- and small-cap names. Biotech’s Big Four are just about 20% of FBT’s weight.